Caplin Point Laboratories Limited (BOM:524742)
1,739.65
-7.25 (-0.42%)
At close: Feb 12, 2026
Caplin Point Laboratories Revenue
Caplin Point Laboratories had revenue of 5.43B INR in the quarter ending December 31, 2025, with 10.10% growth. This brings the company's revenue in the last twelve months to 20.92B, up 10.65% year-over-year. In the fiscal year ending March 31, 2025, Caplin Point Laboratories had annual revenue of 19.40B with 14.35% growth.
Revenue (ttm)
20.92B
Revenue Growth
+10.65%
P/S Ratio
6.32
Revenue / Employee
5.27M
Employees
3,966
Market Cap
132.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19.40B | 2.43B | 14.35% |
| Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
| Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
| Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
| Mar 31, 2021 | 10.62B | 1.98B | 22.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 79.18B |
| Granules India | 50.92B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 38.01B |
| FDC Limited | 20.78B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 18.17B |
Caplin Point Laboratories News
- 7 days ago - Caplin Point Laboratories Ltd (BOM:524742) Q3 2026 Earnings Call Highlights: Navigating Growth ... - GuruFocus
- 7 days ago - Q3 2026 Caplin Point Laboratories Ltd Earnings Call Transcript - GuruFocus
- 17 days ago - Caplin Point subsidiary receives USFDA approval for Methylprednisolone Acetate Injectable - Business Upturn
- 2 months ago - Caplin Point Laboratories subsidiary secures USFDA approval for Generic Linezolid Injection - Business Upturn
- 2 months ago - Caplin Point Laboratories subsidiary receives USFDA approval for Acetaminophen Injection ANDA - Business Upturn
- 3 months ago - Caplin Point Laboratories Ltd (BOM:524742) Q2 2026 Earnings Call Highlights: Strong Revenue ... - GuruFocus
- 3 months ago - Q2 2026 Caplin Point Laboratories Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Caplin Point subsidiary gets USFDA nod for Milrinone Lactate in 5% Dextrose Injection - Business Upturn